Breast Cancer Coverage from Every Angle
Editor:
William J. Gradishar, MD, FACP, FASCO
Advertisement
Advertisement

Available Clinical Trials

Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study
A Dose-escalation Study of the Safety and Pharmacology of DAN-222
A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice
Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)
A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)
A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY)
A Phase III Study of Presurgical Trastuzumab Deruxtecan Alone or followed by THP Compared to Standard Treatment
A Randomized Phase II Study of Pembrolizumab, an anti-PD-1 Antibody, in Combination with Carboplatin vs Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease
A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)
A Randomized Phase II Window-of-opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions
A single arm phase II study of ADjuvant Endocrine therapy, subcutaneous Pertuzumab, and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptorpositive, HER2-positive breast cancer (ADEPT)
A single arm phase II study of ADjuvant Endocrine therapy, subcutaneous Pertuzumab, and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive, HER2-positive breast cancer (ADEPT)
Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Effect of radiotherapy for breast cancer on shoulder health
Hormonal Therapy after Pertuzumab and Trastuzumab for the Treatment of Hormone Receptor Positive, HER2 Positive Breast Cancer
Mobile Device CBT for Chemotherapy-Related Cognitive Dysfunction: A Multi-Center Randomized Controlled Trial
Older Breast Cancer Patients: Risk for Cognitive Decline
Phase II Trial of a 9-Day Course of Whole Breast Radiotherapy for Early Stage Breast Cancer
A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity
Rare Breast Tumor Registry
Tomosynthesis Mammographic Imaging Screening Trial (TMIST) EA1151
Copyright © 2023 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.